SCHEMBL560055

SCHEMBL560055

O=C(O)C=CC=CC=Cc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.68
HDAC4 P56524 3/20 0.68
HDAC1 Q13547 3/20 0.68
HDAC2 Q92769 3/20 0.68
HDAC8 Q9BY41 3/20 0.68
HDAC6 Q9UBN7 3/20 0.68
HDAC7 Q8WUI4 2/20 0.68
HDAC10 Q969S8 2/20 0.68
HDAC11 Q96DB2 2/20 0.68
HDAC9 Q9UKV0 2/20 0.68
HDAC5 Q9UQL6 2/20 0.68
TNKS O95271 1/20 0.68
HCAR2 Q8TDS4 1/20 0.68
TNKS2 Q9H2K2 1/20 0.68
MAOB P27338 8/20 0.61
ALDH1A1 P00352 3/20 0.56
MAPT P10636 3/20 0.56
CYP1A2 P05177 3/20 0.56
LMNA P02545 3/20 0.56
CYP2D6 P10635 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10818746 1.00 HDAC3 (0.68) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL560054 1.00 HDAC3 (0.68) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL27548448 1.00 HDAC3 (0.68) HDAC3HDAC4HDAC1HDAC2HDAC8
Juarezic Acid SCHEMBL436113 0.98 HDAC3 (0.71) HDAC3HDAC4HDAC1HDAC2HDAC8
Juarezic Acid SCHEMBL474728 0.98 HDAC3 (0.71) HDAC3HDAC4HDAC1HDAC2HDAC8
Juarezic Acid SCHEMBL15119 0.98 HDAC3 (0.71) HDAC3HDAC4HDAC1HDAC2HDAC8
Juarezic Acid SCHEMBL144681 0.98 HDAC3 (0.71) HDAC3HDAC4HDAC1HDAC2HDAC8
Juarezic Acid SCHEMBL144680 0.98 HDAC3 (0.71) HDAC3HDAC4HDAC1HDAC2HDAC8
Juarezic Acid SCHEMBL11522747 0.98 HDAC3 (0.71) HDAC3HDAC4HDAC1HDAC2HDAC8
Juarezic Acid SCHEMBL3280210 0.96 HDAC3 (0.68) HDAC3HDAC4HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110288168-A1 HISTONE DEACETYLASE INHIBITORS ERRANT GENE THERAPEUTICS, LLC 2011-11-24 US claimed
US-7842727-B2 Histone deacetylase inhibitors ERRANT GENE THERAPEUTICS, LLC (US) 2010-11-30 US claimed
WO-2008011074-A2 HISTONE DEACETYLASE INHIBITORS ERRANT GENE THERAPEUTICS, LLC (US) 2008-01-24 WO claimed
US-20070037869-A1 Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid ERRANT GENE THERAPEUTICS, LLC 2007-02-15 US claimed
EP-1408946-A4 HISTONE DEACETYLASE INHIBITORS CIRCAGEN PHARMACEUTICAL (US) 2004-06-09 EP claimed
EP-1408946-A2 HISTONE DEACETYLASE INHIBITORS Circagen Pharmaceutical (US) 2004-04-21 EP claimed
EP-1260626-A2 Process for bonding fibrous web CAMELOT SUPERABSORBENTS LTD (CA) 2002-11-27 EP claimed
WO-2002076941-A2 HISTONE DEACETYLASE INHIBITORS CIRCAGEN PHARMACEUTICAL (US) 2002-10-03 WO claimed
US-20020143052-A1 Histone deacetylase inhibitors ANGELA CHEN SABELLA 2002-10-03 US claimed
US-20020143037-A1 Histone deacetylase inhibitors CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION 2002-10-03 US claimed
EP-0956385-A1 PROCESS FOR BONDING FIBROUS WEB CAMELOT SUPERABSORBENTS LTD (CA) 1999-11-17 EP claimed
WO-1998032906-A1 PROCESS FOR BONDING FIBROUS WEB CAMELOT SUPERABSORBENTS LIMITED (CA) 1998-07-30 WO claimed
US-3950600-A Thermosensitive element, and its employ in the thermographic reproduction or record systems ING. C. OLIVETTI & C., S.P.A. (IT) 1976-04-13 US claimed
US-9486421-B2 Treatment of lung cells with histone deacetylase inhibitors ERRANT GENE THERAPEUTICS, LLC (US) 2016-11-08 US disclosed
EP-2489521-B1 HEAT-SENSITIVE RECORDING MATERIAL OJI HOLDINGS CORP (JP) 2013-12-11 EP disclosed
US-8420698-B2 Histone deacetylase inhibitors ERRANT GENE THERAPEUTICS, LLC (US) 2013-04-16 US disclosed
EP-0101319-B1 FIBROUS WEBS OF ENHANCED BULK AND METHOD OF MANUFACTURING SAME James River-Norwalk, Inc. (US) 1987-01-21 EP disclosed
US-4488932-A HAMMER MILLING, DISPERSION IN AQUEOUS FOAM, PAPERMAKING JAMES RIVER-DIXIE/NORTHERN, INC. (US) 1984-12-18 US disclosed
EP-0101319-A2 Fibrous webs of enhanced bulk and method of manufacturing same James River-Norwalk, Inc. (US) 1984-02-22 EP disclosed
US-3950600-A Thermosensitive element, and its employ in the thermographic reproduction or record systems ING. C. OLIVETTI & C., S.P.A. (IT) 1976-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143052-A1 Histone deacetylase inhibitors HDAC1, HDAC11, HDAC9 HDAC3 7/4885HDAC4 14/4885HDAC1 1/4885
US-20020143037-A1 Histone deacetylase inhibitors HDAC1, HDAC9, HDAC11 HDAC3 5/4885HDAC4 13/4885HDAC1 1/4885
US-20110288168-A1 HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC6, HDAC5 HDAC3 6/4885HDAC4 10/4885HDAC1 1/4885
US-20070037869-A1 Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid HDAC5, HDAC1, ZNF277 HDAC3 7/4885HDAC4 16/4885HDAC1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.